Literature DB >> 17618058

The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats.

S Zhang1, L Lin, S Kaur, S Thankachan, C Blanco-Centurion, M Yanagisawa, E Mignot, P J Shiromani.   

Abstract

Narcolepsy is linked to a widespread loss of neurons containing the neuropeptide hypocretin (HCRT), also named orexin. A transgenic (TG) rat model has been developed to mimic the neuronal loss found in narcoleptic humans. In these rats, HCRT neurons gradually die as a result of the expression of a poly-glutamine repeat under the control of the HCRT promoter. To better characterize the changes in HCRT-1 levels in response to the gradual HCRT neuronal loss cerebrospinal fluid (CSF) HCRT-1 levels were measured in various age groups (2-82 weeks) of wild-type (WT) and TG Sprague-Dawley rats. TG rats showed a sharp decline in CSF HCRT-1 level at week 4 with levels remaining consistently low (26%+/-9%, mean+/-S.D.) thereafter compared with WT rats. In TG rats, HCRT-1 levels were dramatically lower in target regions such as the cortex and brainstem (100-fold), indicating decreased HCRT-1 levels at terminals. In TG rats, CSF HCRT-1 levels significantly increased in response to 6 h of prolonged waking, indicating that the remaining HCRT neurons can be stimulated to release more neuropeptide. Rapid eye movement (REM) sleep in TG rats (n=5) was consistent with a HCRT deficiency. In TG rats HCRT immunoreactive (HCRT-ir) neurons were present in the lateral hypothalamus (LH), even in old rats (24 months) but some HCRT-ir somata were in various stages of disintegration. The low output of these neurons is consistent with a widespread dysfunction of these neurons, and establishes this model as a tool to investigate the consequences of partial hypocretin deficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618058      PMCID: PMC2042962          DOI: 10.1016/j.neuroscience.2007.05.029

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  30 in total

1.  Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.

Authors:  Y Yoshida; N Fujiki; T Nakajima; B Ripley; H Matsumura; H Yoneda; E Mignot; S Nishino
Journal:  Eur J Neurosci       Date:  2001-10       Impact factor: 3.386

2.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

3.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.

Authors:  Emmanuel Mignot; Gert Jan Lammers; Beth Ripley; Michele Okun; Sonia Nevsimalova; Sebastiaan Overeem; Jitka Vankova; Jed Black; John Harsh; Claudio Bassetti; Harald Schrader; Seiji Nishino
Journal:  Arch Neurol       Date:  2002-10

4.  Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat.

Authors:  D Gerashchenko; M D Kohls; M Greco; N S Waleh; R Salin-Pascual; T S Kilduff; D A Lappi; P J Shiromani
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

5.  Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness.

Authors:  Jamie M Zeitzer; Christine L Buckmaster; Karen J Parker; Craig M Hauck; David M Lyons; Emmanuel Mignot
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

6.  The diurnal rhythm of hypocretin in young and old F344 rats.

Authors:  Frank Desarnaud; Eric Murillo-Rodriguez; Ling Lin; Man Xu; Dmitry Gerashchenko; Samara N Shiromani; Seiji Nishino; Emmanuel Mignot; Priyattam J Shiromani
Journal:  Sleep       Date:  2004-08-01       Impact factor: 5.849

7.  Relationship between CSF hypocretin levels and hypocretin neuronal loss.

Authors:  Dmitry Gerashchenko; Eric Murillo-Rodriguez; Ling Lin; Man Xu; Laura Hallett; Seiji Nishino; Emmanuel Mignot; Priyattam J Shiromani
Journal:  Exp Neurol       Date:  2003-12       Impact factor: 5.330

8.  Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat.

Authors:  Carsten T Beuckmann; Christopher M Sinton; S Clay Williams; James A Richardson; Robert E Hammer; Takeshi Sakurai; Masashi Yanagisawa
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

9.  Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.

Authors:  Jon T Willie; Richard M Chemelli; Christopher M Sinton; Shigeru Tokita; S Clay Williams; Yaz Y Kisanuki; Jacob N Marcus; Charlotte Lee; Joel K Elmquist; Kristi A Kohlmeier; Christopher S Leonard; James A Richardson; Robert E Hammer; Masashi Yanagisawa
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

10.  Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement.

Authors:  M-F Wu; J John; N Maidment; H A Lam; J M Siegel
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-11       Impact factor: 3.619

View more
  25 in total

1.  Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins.

Authors:  H Schwimmer; H M Stauss; F Abboud; S Nishino; E Mignot; J M Zeitzer
Journal:  J Appl Physiol (1985)       Date:  2010-08-12

2.  Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation.

Authors:  Jasbir Dalal; Jee Hoon Roh; Susan E Maloney; Afua Akuffo; Samir Shah; Han Yuan; Brie Wamsley; Wendell B Jones; Cristina de Guzman Strong; Paul A Gray; David M Holtzman; Nathaniel Heintz; Joseph D Dougherty
Journal:  Genes Dev       Date:  2013-02-21       Impact factor: 11.361

3.  Orexin receptor subtype activation and locomotor behaviour in the rat.

Authors:  W K Samson; S L Bagley; A V Ferguson; M M White
Journal:  Acta Physiol (Oxf)       Date:  2009-11-04       Impact factor: 6.311

4.  Cerebrospinal fluid hypocretin (orexin) levels are elevated by play but are not raised by exercise and its associated heart rate, blood pressure, respiration or body temperature changes.

Authors:  M-F Wu; R Nienhuis; N Maidment; H A Lam; J M Siegel
Journal:  Arch Ital Biol       Date:  2011-11-07       Impact factor: 1.000

Review 5.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

6.  Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats.

Authors:  Camille Planty; Corey P Mallett; Kevin Yim; Jorge C G Blanco; Marina Boukhvalova; Thomas March; Robbert van der Most; Eric Destexhe
Journal:  Hum Vaccin Immunother       Date:  2016-09-14       Impact factor: 3.452

7.  A consensus definition of cataplexy in mouse models of narcolepsy.

Authors:  Thomas E Scammell; Jon T Willie; Christian Guilleminault; Jerome M Siegel
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

8.  Entrainment of temperature and activity rhythms to restricted feeding in orexin knock out mice.

Authors:  Satvinder Kaur; Stephen Thankachan; Suraiya Begum; Carlos Blanco-Centurion; Takeshi Sakurai; Masashi Yanagisawa; Priyattam J Shiromani
Journal:  Brain Res       Date:  2008-02-21       Impact factor: 3.252

Review 9.  Identifying essential cell types and circuits in autism spectrum disorders.

Authors:  Susan E Maloney; Michael A Rieger; Joseph D Dougherty
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

10.  Effects of hypocretin (orexin) neuronal loss on sleep and extracellular adenosine levels in the rat basal forebrain.

Authors:  Eric Murillo-Rodriguez; Meng Liu; Carlos Blanco-Centurion; Priyattam J Shiromani
Journal:  Eur J Neurosci       Date:  2008-09-09       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.